A Modern Approach to
Cancer Testing

IONIQ Sciences is at the forefront of early cancer detection

Cancer is a scourge on society. One in two Americans will be diagnosed with cancer during their lifetime and one in five will die. The five-year cancer survival rates approach 90% when diagnosed in the earliest stages of the disease versus just 10% in the latest stages. 

We believe it doesn’t have to be this way. 

Expanding from a
Single Cancer
Test to a
Multi-Cancer Screen

Early detection saves lives and money by detecting cancer at its earliest, most-treatable stages. We're well-positioned to develop a Multi-Cancer Screen by leveraging our lung test, breast test, proprietary technology, substantial bioimpedance database, and our deep clinical experience.

IONIQ Development Pipeline

ProLung Test - FDA Breakthrough Device
Breast Cancer Test
Multi-Cancer Screen
LUNA 3 next-gen, portable platform

Clinical Data

Deep clinical evidence library with data collected from more than 1,400 subjects demonstrating dramatic improvement over today's standard of care

Breakthrough Device

IONIQ's ProLung Test designated “Breakthrough Device” by US FDA for its life-enhancing potential

Premier Clinical Sites

More than 25 premier cancer institutions across 3 continents have participated in our clinical trials

World-Class Advisors

Collaborating with medical and scientific experts

Intellectual Property

Robust, growing intellectual portfolio of 22 issued and filed patents plus expert know-how

Years in the Making

IONIQ Recent News

IONIQ Sciences visual overview

Salt Lake City, UT, February 2, 2023 – We’re delighted to unveil this visual overview of the modernization of early-stage cancer detection. IONIQ measures the body’s immune response to the presence of cancer in its earliest, most-treatable stages. And we’re doing it with no needles,

IONIQ Sciences to Present at Biotech Showcase

Salt Lake City, UT, January 5, 2023 – ProLung, Inc. dba IONIQ Sciences, Inc. (“IONIQ” or the “Company”) today announced it is presenting in person at Biotech Showcase™, the investor conference for innovators. Mr. Jared Bauer, CEO, will present IONIQ Sciences at the Biotech Showcase on January

IONIQ is “Clinical Diagnostics Solution of the Year 2022”

Salt Lake City, UT, December 19, 2022 – IONIQ Sciences, Inc. (“IONIQ” or the “Company”) is honored to be recognized as the “Clinical Diagnostics Solution of the Year 2022” by BioTech Breakthrough Awards (link). The IONIQ team is humbled by this award and recognition of our mission

Standards & Certifications

Meet the Team

Proud to be part of BioHive, the Nations Fastest Growing Life Science Hub.

By embracing diversity and collaboration, BioHive has become the fastest-growing life science community in America. And our innovations are improving the lives of millions of patients.